Gene Polymorphism & Treatment-Symptoms in Lung Cancer

描述（由申请人提供）：该职业发展奖的目的是为候选人Cielito Reyes-Gibby博士提供将分子/遗传流行病学和先进的统计方法应用于癌症相关症状研究所需的经验和知识。 Reyes-Gibby博士的职业目标是成为一名成熟的症状研究人员。 这一目标建立在她以前在流行病学，统计学，调查研究和护理培训。她从一个最近晋升的助理教授到一个独立的研究人员的转变将发生在U.T.M.D.的症状研究系。休斯顿的安德森癌症中心（UTMDACC）。 Reyes-Gibby博士制定了一项全面的教育计划，将在分子/遗传流行病学，高级统计学和免疫学领域提供强化教学。 她已经选择了三位导师来指导她的训练。 Charles Cleeland博士将提供症状研究方面的指导; Margaret Spitz博士将提供分子和遗传流行病学方面的指导; Razelle Kurzrock博士将提供细胞因子研究方面的指导。 她将在德州大学攻读研究生课程。公共卫生学院和多伦多大学生物科学学院。 对于她提出的研究，Reyes-Gibby博士将把遗传数据纳入开发与肺癌治疗相关的症状时程的稳健定量模型。 她的具体假设是，细胞因子基因多态性将是症状结果的预测因子。 如果得到证实，这一假设将有助于更好地理解症状产生的分子基础，并为治疗严重和持续症状的新方法奠定基础。 拟定的研究旨在建立在NIH资助的（Charles Cleeland，PhD，主要研究者）在UT MDACC接受一线化疗的肺癌患者（NSCLC，晚期）症状纵向研究和美国癌症协会资助的（Charles Cleeland，PhD，主要研究者）在UTMDACC接受根治性手术的肺癌患者（NSCLC I-IliA期）症状纵向研究的基础上。 这些资助的研究提供了评估基因多态性与疾病分期（研究1为晚期，研究2为早期）和治疗（化疗和手术治疗）相关症状之间关系的机会。 由于肺癌患者患有严重的衰弱症状，而肺癌是美国男性和女性癌症死亡的主要原因，因此该项目的发现具有巨大的公共卫生意义。

DESCRIPTION (provided by applicant): The objective of this career development award is to provide the candidate, Dr. Cielito Reyes-Gibby, the experience and knowledge necessary to apply molecular/genetic epidemiology and advanced statistical methods to the study of cancer-related symptoms. Dr. Reyes-Gibby's career goal is to become an established symptom researcher. This goal builds upon her previous training in epidemiology, statistics, survey research, and nursing. Her transition from that of a recently promoted Assistant Professor to an independent researcher will take place at the Department of Symptom Research at U.T.M.D. Anderson Cancer Center (UTMDACC) in Houston. Dr. Reyes-Gibby has developed a comprehensive education plan that will provide intensive instruction in the areas of molecular/genetic epidemiology, advanced statistics, and immunology. She has chosen three mentors who will supervise her training. Dr. Charles Cleeland will provide mentorship in symptom research; Dr. Margaret Spitz will provide mentorship in molecular and genetic epidemiology; and Dr. Razelle Kurzrock will provide mentorship in cytokine research. She will attend graduate courses at the U.T. School of Public Health and U.T School of Biological Sciences. For her proposed research, Dr. Reyes-Gibby will incorporate genetic data in developing robust quantitative models for the time course of symptoms in relation to lung cancer therapy. Her specific hypothesis is that cytokine gene polymorphism will be a predictor of symptom outcomes. If confirmed, this hypothesis creates a better understanding of the molecular basis of symptom production and a foundation for a new approach to the treatment of severe and persistent symptoms. The studies proposed are designed to build upon an NIH-funded (Charles Cleeland, PhD, Principal Investigator) longitudinal study of symptoms of lung cancer patients (NSCLC, advanced stage) admitted for first line chemotherapy at UT MDACC and an American Cancer Society-funded (Charles Cleeland, PhD, Principal Investigator) longitudinal study of symptom of lung cancer patients (NSCLC stage I-IliA) undergoing curative surgery at the UTMDACC. These funded studies provide the opportunity to assess the relationship between gene polymorphisms and symptoms related to disease stage (late stage for study 1 and early stage disease for study 2) and therapy (chemotherapy and surgical therapy). Since lung cancer patients suffer from severe debilitating symptoms and lung cancer is the leading cause of cancer mortality for men and women in the United States, the findings from this project have immense public health significance.